简氏激酶抑制剂可以改善STAT3功能增强患者的临床症状
Shuya Kaneko1, Fumiaki Sakura2, Kay Tanita1
1Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan.
Immunotherapy advances
|March 29, 2024
概括
简氏激酶 (JAK) 抑制剂有效地治疗了四名用信号传感器和转录3 (STAT3) - 功能增益 (GOF) 变体的激活器治疗的患者,改善了常见的自身免疫和淋巴增殖症状.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 遗传学 是一个
- 药理学 药理学是指药理学的学科.
背景情况:
- 在信号传感器和转录3 (STAT3) 基因激活器中的生殖线功能增益 (GOF) 变异会导致免疫的先天错误.
- 这种疾病表现出各种症状,包括自身免疫和淋巴扩散,缺乏已确定的有效治疗方法.
研究的目的:
- 研究Janus激酶抑制剂 (JAKi) 作为治疗STAT3-GOF.患者的疗效.
- 描述用JAKi治疗的患者的临床结果和细胞反应.
主要方法:
- 四名STAT3-GOF患者接受了JAKi的治疗.
- 在开始治疗之前和之后记录了临床症状.
- 来自患者的爱斯坦-巴尔病毒转化淋巴细胞系 (EBV-LCLs) 用细胞刺激试验进行了分析.
主要成果:
- 在接受JAKi治疗后,患者在各种临床症状中显著改善.
- 来自患者的EBV-LCL显示,与对照人群相比,在干白素-6刺激时,STAT3酸化升高.
- 雅克抑制剂有效降低了STAT3通路过活化.
结论:
- 简氏激酶抑制剂代表了管理STAT3-GOF的有希望和有效的治疗选择.
- 四名日本患者的成功治疗证明了JAKi在这种罕见的免疫疾病中的临床实用性.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Amplifying Signals via Enzymatic Cascade
8.5K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.5K


